Oxford BioMedica (OXBDF) Stock Statistics & Valuation Metrics

Oxford BioMedica has a market cap or net worth of $465.96M. The enterprise value is $412.54M.

Oxford BioMedica has 106,093,860 shares outstanding. The number of shares has decreased by -2.65% in one year.

Oxford BioMedica’s return on equity (ROE) is -0.76 and return on invested capital (ROIC) is -23.33%.

The current PE Ratio of Oxford BioMedica is -10.06. Oxford BioMedica’s PEG ratio is -0.12.

In the last 12 months, Oxford BioMedica had revenue of 128.80M and earned -43.19M in profits. Earnings per share was -0.42.

In the last 12 months, operating cash flow was -51.05M and capital expenditures -7.50M, giving a free cash flow of -58.55M billion.

Oxford BioMedica pays an annual dividend of ―, resulting in a dividend yield of ―

Oxford BioMedica upcoming earnings date is Apr 9, 2025, TBA Not Confirmed.

Oxford BioMedica as a current ratio of 2.28, with Debt / Equity ratio of 190.65%

In the past 12 months, Oxford BioMedica has paid 1.34M in taxes.

Oxford BioMedica EV to EBITDA ratio is -33.67, with an EV/FCF ratio of -8.30.

Oxford BioMedica has $60.65M in cash and marketable securities with £108.76M in debt, giving a net cash position of $48.11M billion.

Gross margin is 40.90%, with operating margin of -30.57%, and net profit margin of -33.53%.

The average price target for Oxford BioMedica is $8.81, which is 11.43% higher than the current price. The consensus rating is Moderate Buy